Newswise — LOS ANGELES (June 3, 2022) -- Cedars-Sinai clinicians and scientists, including anti-rejection therapy pioneer Stanley Jordan, MD, will share their latest advances in research at the American Transplant Congress (ATC), June 4-8, 2022, in Boston. The ATC is the joint annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.

During the meeting, Cedars-Sinai physicians and scientists will be available for in-person and virtual interviews on a variety of clinical and research topics related to transplantation and immunology.

Jordan headlines the meeting with a symposium on the diagnosis and treatment of antibody-mediated rejection in kidney transplant patients. Other highlights of this year’s ATC include research tracking immune responses in patients after COVID-19 vaccination, and innovations in immunomodulatory therapies—drugs that help modify the response of the immune system—in preventing organ rejection.

For more information about any of the below presentations, or to schedule an interview with one of the Cedars-Sinai transplant experts, please contact Sarah Lichtman at 540-834-7954 or [email protected].

Sunday, June 5
Rapid Oral Abstract Presentation: Pre-Emptive Rituximab to Prevent Post Transplant Lymphoproliferative Disorder (PTLD) in Pediatric Kidney Transplant Recipients With EBV DNAemia: A Case Series From the Pediatric Nephrology Research Consortium (PNRC)
5:40 p.m.
Dechu Puliyanda, MD

Monday, June 6
Program topic: Basic Science/Immunology: SARS-CoV-2 Immunity and Pathogenesis
Lecture: T-cell Immune Responses to SARS-CoV-2 and Variants of Concern in Immunocompromised Individuals
2-2:10 p.m.
Stanley Jordan, MD

Rapid Oral Abstract Presentation: Assessment of Humoral and Cellular Immune Responses to SARS-CoV-2 Vaccination in Immunocompromised Renal Allograft Recipients
4:50 p.m.
Bongha Shin, PhD

Tuesday, June 7
Symposium: ABMR in Renal Transplantation: Immune Mechanisms, Diagnostic Criteria, and Therapeutic Advances
12:45-1:45 p.m.
Lunch provided, Sheraton Boston Hotel (Constitution Ballroom)
Stanley Jordan, MD

Rapid Fire Oral Abstract Presentation: Clazakizumab ® (anti-IL-6) Desensitization in Highly-HLA Sensitized Patients Awaiting Kidney Transplant (nct03380962): Long-Term Follow-Up
3:40 p.m.
Ashley Vo, PharmD

Rapid Fire Oral Abstract Presentation: Histopathology at Diagnosis and One-Year Outcomes in Antibody Mediated Rejection in Pediatric Kidney Transplant Recipients: Preliminary Findings From the Paramour “Pediatric Renal Amr Outcomes”
4:40 p.m.
Dechu Puliyanda, MD

Wednesday, June 8
Program topic: Basic Science/Immunology & Translational: We Need Car T-cells to Effectively Desensitize High PRA Patients
Lecture: Defining the Current Status of Desensitization and the Future of Potential Options
Lecture: 10:15-10:25 a.m. 
Stanley Jordan, MD